Richard Kim, MD, Moffitt Cancer Center, Tampa, FL, provides an overview of actionable mutations and targeted therapies for patients with colorectal cancer (CRC). Whilst anti-EFGR antibodies are not efficacious in KRAS-mutant CRC, KRAS G12C can be targeted with sotorasib and adagrasib. HER2-mutant CRC can be treated with tucatinib and trastuzumab, whereas BRAF-mutant CRC can be targeted with encorafenib and cetuximab. Testing the mismatch repair (MMR) status is additionally useful, where patients with deficient MMR CRC benefit from immunotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: [ Ссылка ]

свернуть